Waters to merge with Becton's biosciences and diagnostics arm in $17.5 billion deal

Waters Corp announced it will merge with Becton, Dickinson and Company’s Biosciences & Diagnostic Solutions business in a deal valued at approximately $17.5 billion. Structured as a tax-efficient Reverse Morris Trust, the transaction is expected to create a combined entity with projected 2025 revenues of about $6.5 billion.

Analysis

Waters Corp (WAT) is set to merge with Becton, Dickinson and Company's (BDX) Biosciences & Diagnostic Solutions business in a significant transaction valued at approximately $17.5 billion. The deal is structured as a tax-efficient Reverse Morris Trust, signaling a strategic move to unlock value by spinning off and combining the units. This merger will create a new, sizeable entity in the healthcare sector with a specific forward-looking target: a projected revenue of about $6.5 billion for fiscal year 2025. While the per-ticker sentiment for both WAT and BDX is positive at 0.6, indicating a favorable market reception to the merger itself, the overall article's tone is cautious with a neutral sentiment score. This suggests the transaction, while strategically sound on its own merits, is being viewed within a context of broader market uncertainty.

Key Decisions for Investors

• Investors should analyze the projected $6.5 billion in 2025 revenue for the combined entity against the $17.5 billion valuation to assess implied multiples and the potential for revenue and cost synergies.
• The use of a Reverse Morris Trust structure is a key financial detail; monitoring the deal's progression towards a successful, tax-efficient close is critical for shareholders of both Waters Corp and Becton Dickinson.
• Given the positive per-ticker sentiment, the deal may present a bullish catalyst for the involved equities, but this should be weighed against the cautious overall market tone, which could impact post-announcement share performance.